Mount Sinai researchers develop novel therapy that could be effective in many cancers
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery, a journal of the American Association for Cancer Research, in July. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

Chemotherapy can induce mutations that lead to pediatric leukemia relapse
(St. Jude Children's Research Hospital) A collaboration led by St. Jude Children's Research Hospital, Shanghai Children's Medical Center and others revealed how thiopurines produce mutations that lead to multi-drug resistant leukemia and relapse. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

Research identifies potential role of 'junk DNA' sequence in aging, cancer
(Washington State University) Researchers at Washington State University have recently identified a DNA region known as VNTR2-1 that appears to drive the activity of the telomerase gene, which has been shown to prevent aging in certain types of cells. Knowing how the telomerase gene is regulated and activated and why it is only active in certain cell types could someday be the key to understanding how humans age and how to stop the spread of cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

Novel imaging agent identifies biomarker for iron-targeted cancer therapies
(Society of Nuclear Medicine and Molecular Imaging) A new radiotracer that detects iron in cancer cells has proven effective, opening the door for the advancement of iron-targeted therapies for cancer patients. The radiotracer, 18F-TRX, can be used to measure iron concentration in tumors, which can help predict whether a not the cancer will respond to treatment. This research was published in the July issue of The Journal of Nuclear Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

Phase two CD19-antibody-drug conjugate trial demonstrates promise for aggressive lymphoma
(Medical University of South Carolina) MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma. The results of the single-arm, phase 2 trial were published online in May 2021 in Lancet Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

American Society for Colposcopy and Cervical Pathology discusses updated American Cancer Society guidelines on cervical cancer screening
(Wolters Kluwer Health) Last year, the American Cancer Society (ACS) issued an updated set of guidelines for cervical cancer screening - emphasizing the shift toward screening with primary human papillomavirus (HPV) testing. While the ACS recommendation accounts for a transition period to implement primary HPV screening, additional factors should be considered to operationalize these guidelines, according to a special white paper in the July issue of the Journal of Lower Genital Tract Disease (JLGTD), official journal of ASCCP. The journal is published in the Lippincott portfolio by Wolters Kluwer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

New organ-on-a-chip finds crucial interaction between blood, ovarian cancer tumors
(Texas A&M University) Researchers at Texas A&M University are pushing organ-on-a-chip devices to new levels that could change the way clinicians approach cancer treatment, particularly ovarian cancer. A team has recently submitted a patent disclosure with the Texas A&M Engineering Experiment Station. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: Fgr and Numb in retinoic differentiation and G0 arrest of non-APL AML cells
(Impact Journals LLC) In sum the Oncotarget data support a paradigm where signaling molecules bound to a Numb scaffold in a signalsome are activated by RA-induced Fgr expression (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

Study on chromosomal rearrangements in yeast reveals potential avenue for cancer therapy
(Osaka University) Researchers from Osaka University have found that the attachment of a ubiquitin molecule to a protein called PCNA at the lysine 107 position causes gross chromosomal rearrangements. This lysine is located where two PCNA molecules interact, and the ubiquitin attachment to it may change the ring structure they form. The ubiquitin attachment occurs through the action of Rad8 (a ubiquitin ligase) and Mms2-Ubc4 (a ubiquitin conjugating enzyme). This implies that inhibiting the human equivalent of this ubiquitination could prevent cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: news

Geneticists reveal how mutation causes childhood cancer; use drug to reverse its effects
(Trinity College Dublin) Geneticists from Trinity College Dublin have discovered how a specific genetic mutation (H3K27M) causes a devastating, incurable childhood cancer, known as diffuse midline glioma (DMG), and - in lab studies working with model cell types - successfully reverse its effects to slow cancer cell growth with a targeted drug. Their landmark work - just published in leading international journal, Nature Genetics - translates crucial new understanding of the genetics of DMG progression into a highly promising, targeted therapeutic approach and offers significant hope of improved treatments in the future. (S...
Source: EurekAlert! - Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: news

Studies find combination chemotherapy beneficial and cost-effective in sub-Saharan Africa
(UNC Lineberger Comprehensive Cancer Center) Researchers at the UNC Lineberger Comprehensive Cancer Center demonstrated in a clinical trial in Malawi that a five-drug combination chemotherapy provided curative benefit compared to current standard-of care-therapy in people diagnosed with lymphoma, and now they have determined this option is also cost-effective. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: news

Advanced bladder cancers respond to immunotherapy regardless of gene mutation status
(UNC Lineberger Comprehensive Cancer Center) UNC Lineberger researchers and colleagues report a study has demonstrated that patients with advanced bladder cancers whose tumors have a mutated FGFR3 gene respond to immunotherapy in a manner that is similar to patients without that mutation. This discovery runs counter to previous research that suggested FGFR3-mutated bladder cancers should not be treated with immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: news

Mayo Clinic research suggests women over 65 be offered hereditary cancer genetic testing
(Mayo Clinic) A new study by Fergus Couch, Ph.D., of Mayo Clinic Cancer Center, along with collaborators from the CARRIERS consortium, suggests that most women with breast cancer diagnosed over 65 should be offered hereditary cancer genetic testing. The study was published Thursday, July 22, in the Journal of Clinical Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: news

Scientists provide new insight on how to stop transcription of cancer cells
(University of California - Los Angeles Health Sciences) Findings could help pave the way for cancer therapies that target TAF12, potentially stopping transcription in cancer cells and helping decrease the growth of cancerous tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2021 Category: Cancer & Oncology Source Type: news

New approach eradicates breast cancer in mice
(University of Illinois at Urbana-Champaign, News Bureau) A new approach to treating breast cancer kills 95-100% of cancer cells in mouse models of human estrogen-receptor-positive breast cancers and their metastases in bone, brain, liver and lungs. The newly developed drug, called ErSO, quickly shrinks even large tumors to undetectable levels. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2021 Category: Cancer & Oncology Source Type: news

Study: Ibrutinib effective treatment for difficult to treat forms of hairy cell leukemia
(Ohio State University Wexner Medical Center) The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2021 Category: Cancer & Oncology Source Type: news

Hundreds of chemicals, many in consumer products, could increase breast cancer risk
(Silent Spring Institute) a new study shows that several hundred common chemicals, including pesticides, ingredients in consumer products, food additives, and drinking water contaminants, could increase the risk of breast cancer by causing cells in breast tissue to produce more of the hormones estrogen or progesterone. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2021 Category: Cancer & Oncology Source Type: news

Scientists identify protein markers related to the most common form of leukemia
(Wiley) Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. New research published in the Journal of Leukocyte Biology reveals that certain protein markers may indicate which patients have stable forms of CLL and which have more aggressive types. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: Subtypes of thymic epithelial tumors independent of WHO type
(Impact Journals LLC) These Oncotarget results may reflect the unselected patient population enrolled in these studies, including no selection for WHO histologic subtype or molecular aberrations. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2021 Category: Cancer & Oncology Source Type: news

Study identifies MET amplification as driver for some non-small cell lung cancers
(University of Colorado Anschutz Medical Campus) A study led by CU Cancer Center member D. Ross Camidge, MD, PhD, has helped define MET amplification as an actionable driver for some non-small cell lung cancers (NSCLC). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 20, 2021 Category: Cancer & Oncology Source Type: news

Mark Foundation funds Jackson Laboratory scientists to study immunotherapy side effects
(The Mark Foundation for Cancer Research) The Mark Foundation for Cancer Research announces a $1 million grant to The Jackson Laboratory to study the relationship between genetics and the harmful side effects of cancer immunotherapy using mice engineered with humanized immune systems. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 20, 2021 Category: Cancer & Oncology Source Type: news

Preparing T cells for the long haul
(La Jolla Institute for Immunology) In a new Nature Immunology study, researchers at La Jolla Institute for Immunology (LJI) report that T cells can be engineered to clear tumors without succumbing to T cell exhaustion. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 19, 2021 Category: Cancer & Oncology Source Type: news

Researchers discover how cancer cells that spread to lymph nodes avoid immune destruction
(Massachusetts General Hospital) New research provides insights on why cancer cells that spread to lymph nodes can often avoid being eliminated by immune cells. The blood pressure drug losartan may help overcome this immune evasion. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 19, 2021 Category: Cancer & Oncology Source Type: news

Why identical mutations cause different types of cancer
(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) Why do alterations of certain genes cause cancer only in specific organs of the human body? Scientists at the German Cancer Consortium (DKTK), the Technical University of Munich (TUM), and the University Medical Center G ö ttingen have now demonstrated that cells originating from different organs are differentially susceptible to activating mutations in cancer drivers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 19, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: Cutaneous apocrine sweat gland carcinoma
(Impact Journals LLC) Together these Oncotarget results describe the first ever CAC case with a BRCAness genetic background. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 19, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: Caspase-11 and AIM2 inflammasome involved in COPD and lung adenocarcinoma
(Impact Journals LLC) The Oncotarget authors found that AIM2 inflammasome is at the crossroad between COPD and lung cancer in that its higher presence is correlated to lower survival rate of smoking COPD adenocarcinoma patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 19, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: Biomechanics in response to drug in hypoxia by atomic force spectroscopy
(Impact Journals LLC) These Oncotarget results show that a degree of chemotherapeutic drug effects on biomechanical and biophysical properties of cancer cells is distinguishable in normoxia and hypoxia` (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 19, 2021 Category: Cancer & Oncology Source Type: news

Personalized immunotherapy response studied in body-on-a-chip cancer models
(Wake Forest Baptist Medical Center) Wake Forest researchers and clinicians are using patient-specific tumor 'organoid' models as a preclinical companion platform to better evaluate immunotherapy treatment for appendiceal cancer, (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 19, 2021 Category: Cancer & Oncology Source Type: news

To die or not to die in response to stress, a decision regulated by MK2 protein levels
(Institute for Research in Biomedicine (IRB Barcelona)) Researchers at IRB Barcelona unveil a pathway that determines the fate of cells in response to stress conditions and identify an important mechanism that recovers cell balance. The results have been published in the journal PNAS. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 19, 2021 Category: Cancer & Oncology Source Type: news

Ficlatuzumab plus chemotherapy may benefit patients with relapsed/refractory AML
(American Association for Cancer Research) The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 16, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: RAS reversion in colorectal cancer patients treated with bevacizumab
(Impact Journals LLC) This Oncotarget finding might have potential therapeutic implications, as anti-EGFR could be reconsidered in primarily RAS mutant patients reverted to a wild-type status after bevacizumab exposure. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 16, 2021 Category: Cancer & Oncology Source Type: news

Ludwig Cancer Research study reveals even transient chromosomal errors can initiate cancer
(Ludwig Institute for Cancer Research) A Ludwig Cancer Research study has found that inducing random chromosome instability (CIN) events in mice for as little as one week is enough to trigger harmful chromosomal patterns in cells that spur the formation of tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 16, 2021 Category: Cancer & Oncology Source Type: news

Cellular push and pull, a key to the body's response to processes such as cancer
(Institute for Bioengineering of Catalonia (IBEC)) Researchers led by Pere Roca-Cusachs at the Institute for Bioengineering of Catalonia (IBEC) and Isaac Almendros at IDIBAPS discover how force dynamics affect cells, and living tissues. The results give an insight into the critical mechanical processes that occur in different diseases such as cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 16, 2021 Category: Cancer & Oncology Source Type: news

New Sinai Health research finds common denominator linking all cancers
(Lunenfeld-Tanenbaum Research Institute) All cancers fall into just two categories, according to new research from scientists at Sinai Health, in findings that could provide a new strategy for treating the most aggressive and untreatable forms of the disease.In new research out this month in Cancer Cell, scientists at the Lunenfeld-Tanenbaum Research Institute (LTRI) divide all cancers into two groups, based on the presence or absence of a protein called the Yes-associated protein, or YAP. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 16, 2021 Category: Cancer & Oncology Source Type: news

A noninvasive test to detect cancer cells and pinpoint their location
(Massachusetts Institute of Technology) MIT engineers have created a nanoparticle for cancer diagnosis that can reveal the presence of cancerous proteins through a urine test, and can also function as an imaging agent, pinpointing the tumor location. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 15, 2021 Category: Cancer & Oncology Source Type: news

Can turmeric reduce joint pain during breast cancer treatment?
(University of California - Davis Health) The UC Davis Comprehensive Cancer Center received a $50,000 grant from the Safeway Foundation. The funding will allow researcher Mili Arora to study whether the spice turmeric can provide pain relief for breast cancer patients on oral anti-estrogen drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 15, 2021 Category: Cancer & Oncology Source Type: news

Moffitt Physician receives NCI Cancer Clinical Investigator Team Leadership Award
(H. Lee Moffitt Cancer Center& Research Institute) Zeynep Eroglu, MD, assistant member of the Cutaneous Oncology Department at Moffitt Cancer Center, received the 2021 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 15, 2021 Category: Cancer & Oncology Source Type: news

Routine screening for BI-RADS lesions on automated whole-breast ultrasound
(American Roentgen Ray Society) According to ARRS' American Journal of Roentgenology, return to routine screening for BI-RADS 3 lesions on supplemental automated whole-breast ultrasound (ABUS) substantially reduces the recall rate, while being unlikely to result in adverse outcome. This prospective study supports a recommendation for routine annual follow-up for BI-RADS 3 lesions at supplemental ABUS. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 15, 2021 Category: Cancer & Oncology Source Type: news

Helping working cancer caregivers manage stress
(University of Colorado Anschutz Medical Campus) Bradley received a nearly $4 million grant from the National Cancer Institute to study ways to lessen the impacts of stress specifically on cancer caregivers who are also employed. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 15, 2021 Category: Cancer & Oncology Source Type: news

Screening often misses endometrial cancer in Black women
In this study using a simulated cohort, TVUS endometrial thickness screening missed over four times more cases of endometrial cancer among Black women versus White women owing to the greater prevalence of fibroids and non-endometrioid histology type that occurs among Black women. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 15, 2021 Category: Cancer & Oncology Source Type: news

Low-dose radiotherapy combined with immunotherapy eradicates metastatic cancer in mice
(University of Pittsburgh) More doesn't necessarily mean better - including in cancer treatment. University of Pittsburgh School of Medicine and University of Wisconsin-Madison scientists report today in Science Translational Medicine that combining targeted radiopharmaceutical therapy with immunotherapy significantly boosts eradication of metastatic cancer in mice, even when the radiation is given in doses too low to destroy the cancer outright. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news

Drug combination shows meaningful responses for malignant peritoneal mesothelioma patient
(University of Texas M. D. Anderson Cancer Center) A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news

LETI's research will help apply magnetotactic bacteria in oncology
(Saint Petersburg Electrotechnical University LETI) Kamil Gareev, Associate Professor at ETU " LETI, " justified the prospects of using magnetotactic bacteria to treat malignant tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news

ASH chooses Wiley to publish ASH Clinical News starting in 2022
(Wiley) The American Society of Hematology (ASH), the world's largest professional society concerned with the causes and treatments of blood disorders, and global research and education leader Wiley today announced that, starting in January 2022, Wiley will publish ASH's industry-leading newsmagazine, ASH Clinical News. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news

MD Anderson research highlights for July 14, 2021
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a promising combination therapy for acute myeloid leukemia, understanding mechanisms driving resistance to PARP inhibitors, a therapeutic neoantigen vaccine to treat lung cancer, a novel treatment for triple-negative breast cancer and a new understanding of how telomeres may drive inflammatory bowel disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news

Melanoma of the eye: Preclinical tests show path toward treatment
(University of Alabama at Birmingham) A preclinical study offers hope for treatment of uveal melanoma, a rare and deadly cancer of the eye. A small molecule inhibitor has been identified that dampens the potent drivers of this tumor. In mouse models, the inhibitor strongly limited primary disease in the eye and metastatic tumor dissemination to the liver, and animals survived longer, without overt side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news

COVID precautions may result in more breast cancer deaths
(Oxford University Press USA) A new paper in the Journal of the National Cancer Institute indicates that disruptions in health care due to the COVID 19 pandemic may increase breast cancer deaths. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: CEA as a blood-based biomarker in anal cancer
(Impact Journals LLC) CEA is not associated with survival outcomes in SCCA, and is not a clinically relevant biomarker in this disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news

Unlike other global crises, COVID-19 pandemic did not spark more smoking in its initial stage
(University of Waterloo) Unlike other population-level stressful events such as natural disasters, COVID-19 has not resulted in a net increase in smoking. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news

Study shows Cannabis terpenes provide pain relief, contribute to 'entourage effect'
(University of Arizona Health Sciences) Researchers in the University of Arizona Health Sciences Comprehensive Pain and Addiction Center have found that terpenes mimic cannabinoids and produce similar pain-relieving effects, which are amplified when the two are used together. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 13, 2021 Category: Cancer & Oncology Source Type: news